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Abstract
Background: Patients with rheumatoid arthritis (RA) suffer from co-morbidities that contribute to a shortened
lifespan. Inflammation is important for the development of cardiovascular disease, but little is known on its
relationship with other co-morbidities. We investigated the role of inflammation for the development of new
comorbidities in early RA.
Methods: Since 1995, all patients with early RA in Northern Sweden are included in a prospective study on co-
morbidities, with a total of 950 patients being included. At the time for this study, 726 had been ill for ≥5 years.
Data on co-morbidities, clinical and laboratory disease activity and pharmacological therapy were collected from
patient records and further validated using a questionnaire at RA onset (T0) and after 5 years (T5).
Results: Of the patients, 53.2 % of the patients had one or more co-morbidity at onset, the commonest being:
hypertension (27.3 %), obstructive pulmonary disease (13.9 %), diabetes (8.0 %), hypothyroidism (6.3 %) and malignancy
(5.0 %). After 5 years, 41.0 % had developed at least one new co-morbidity, the most common being: hypertension
(15.1 %), malignancy (7.6 %), stroke/transient ischemic accident (5.1 %), myocardial infarction (4.3 %) and osteoporosis
(3.7 %). Age at disease onset, a raised erythrocyte sedimentation rate (ESR) at inclusion, previous treatment with
glucocorticoids (GC; p < 0.001 for all), extra-articular RA (Ex-RA; p < 0.01), DAS28 (area under the curve) at 24 months
(p < 0.05), previous smoking at inclusion (p = 0.058) and male gender (p < 0.01) were associated with a new co-morbidity
overall at T5. Treatment with biologics (p < 0.05) reduced the risk. In multiple logistic regression modelling, ESR (p = 0.036)
at inclusion was associated with a new co-morbidity after 5 years, adjusted for age, sex, smoking and GC treatment. In a
similar model, Ex-RA (p < 0.05) was associated with a new co-morbidity at T5. In a third model, adjusted for age and sex, a
new pulmonary co-morbidity was associated with a smoking history at inclusion (p < 0.01), but not with ESR.
Conclusion: There was substantial co-morbidity among early RA patients already at disease onset, with considerable new
co-morbidity being added during the first five years. Measures of disease activity were associated with the occurrence of
a new co-morbidity indicating that the inflammation is of importance in this context.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory auto-
immune disease with unknown etiology that primarily
affects the peripheral joints and, over time, leads to loss of
mobility if untreated. RA is also a systemic disease and
many patients have constitutional symptoms (e.g., weight
loss, fatigue, etc.) at disease onset. Some patients also
develop extra-articular manifestations (Ex-RA), a known
risk factor with prognostic implications [1, 2]. It is well-
known that RA patients have increased mortality [3–5] and
shortened life expectancy compared with the general popu-
lation [3, 6, 7]. In clinical practice, it is not unusual that at
their first visit to a rheumatology clinic patients with early
RA already have one or more co-existing diseases [8–11],
with additional increased risk of work-related disability, im-
paired quality of life and substantial societal costs [12].
Some of the co-existent diseases are causally associated with
RA, others occur as a consequence of the pharmacological
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treatment of RA [10, 12, 13]. Co-morbid conditions
that are over-represented in RA patients compared
with the general population include cardiovascular dis-
ease (CVD) [3, 14–17], interstitial lung disease [18–20],
infections [21, 22], gastrointestinal disease [12, 23] and
osteoporosis [24, 25]. There are no convincing data for
evidence of greater risk of malignancy, although a slight
increase in overall risk has been reported [26]. However,
there is a trend towards certain site-specific cancers, such
as lymphoma [26, 27] and lung cancer [26, 28], being
more common in patients with RA. It has been shown
that morbidity [16, 29] and premature mortality [3, 4, 30]
due to CVD is increased in RA patients in comparison to
population rates. Several studies during the past decade
have demonstrated a link between inflammation and the
development of CVD in patients with RA [31–33]. How-
ever, little is known about the importance of the inflam-
matory status in relation to other co-morbidities in
patients with RA.
In the present observational study, an inception cohort
of patients with early RA has been followed prospectively
from disease onset. The aims were: first, to investigate the
presence of co-morbidities at onset of RA in all patients
who had been included; second, to investigate the devel-
opment of new co-morbidities in those who had been ill
for >5 years at follow up, during the first 5 years following
diagnosis of RA; and finally, to assess the role of inflam-
mation in relation to those new co-morbidities.
Methods
By reference to the nation-wide Swedish Early RA Register,
part of the Swedish Rheumatology Quality Register [34],
all eligible patients from the four northernmost counties
of Sweden diagnosed with early RA (i.e., symptomatic
for <12 months), and fulfilling the American Rheuma-
tism Association classification criteria [35] were con-
secutively included from December 1995 in a large
observational study on the progression of RA, including
development of co-morbidities. By November 2012, 950
patients (649 women, 301 men) registered with newly di-
agnosed early RA had been included in the study at the
time of being diagnosed with RA (T0 baseline/inclusion).
By November 2012, 224 patients had been ill for <5 years
and thus, only baseline data have been registered for these
patients. In all, 726 patients had been ill for 5 years or
more and could be evaluated in the 5-year follow-up (T5).
Of these 726 patients, 52 died before they reached 5-year
follow up. No patient was lost to follow up. All patients
were clinically examined regularly by their local rheuma-
tologist, and routine laboratory tests and radiographs of
hands and feet were performed.
According to the study protocol for inclusion into the
Early RA register, the 28-joint count of tender joints
(TJC) and swollen joints (SJC), a visual analog scale
(VAS) for pain and the patient’s global assessment, com-
pletion of the Health Assessment Questionnaire (HAQ)
[36] and measurement of inflammatory markers, i.e.,
erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) were recorded at baseline and after 6, 12,
18, 24, 36, and 60 months. These data were downloaded
for the purpose of this study. The accumulated disease
activity score in 28 joints (DAS28) was calculated only
up to 24 months [37] because data were incomplete
from some centers after 24 months.
The presence of autoantibodies, i.e., rheumatoid factor
(RF), and anti-nuclear antibodies (ANA), was assessed at
baseline by routine laboratory methods in current use at
each of the participating hospitals. Antibodies against cyc-
lic citrullinated peptides/proteins (ACPA) were analyzed
at baseline using enzyme-linked immunoassay (ELISA) for
anti-CCP2 antibodies (Euro-Diagnostica). Genotyping
for PTPN22 1858C/T polymorphisms and HLA–DRB1
(shared epitope; 0101/0401/0404/0405/0408) typing were
performed as previously described [38, 39].
All patient records were carefully examined and data col-
lected according to the study protocol, on co-morbidities
and pharmacological treatment, both at inclusion (T0) and
after 5 years (T5). The patients also completed a self-
reported questionnaire on co-morbidity at T0 and T5 to
further increase the validity of the collected data. The
questionnaire comprised specific questions about CVD
and an open question about other previous and current
co-existing disorders. All co-morbidity data have been
processed in accordance with the classification of diseases
described by Charlson [40]. The basis for the Charlson
instrument is a disorder sub-division consisting of 10 som-
atic disease categories (myocardial, vascular, pulmonary,
neurologic, endocrine, renal, liver, gastrointestinal, cancer/
immune and miscellaneous), each with several sub-groups
[40]. Recorded myocardial and vascular variables were
myocardial infarction (MI)/coronary artery bypass graft
(CABG), stroke/transient ischemic attack (TIA)/deep vein
thrombosis (DVT)/pulmonary embolism (PE), and rup-
tured aortic aneurysm. The procedure and criteria for data
collection of cardiovascular co-morbidity has previously
been described in detail [41].
For all other diagnoses, including malignancy and neuro-
logic, renal, liver and gastrointestinal disease, a diagnosis
recorded by a clinician was accepted as a sufficient basis
for registration. The presence of hypertension was further
defined as receiving anti-hypertensive treatment. A diag-
nosis of pulmonary disease, including asthma and chronic
obstructive pulmonary disease (COPD), required continu-
ous or intermittent bronchodilator treatment. Endocrine
disease was defined as the presence of diabetes mellitus,
osteoporosis, hyperparathyroidism, hyperthyroidism, goitre
and hypothyroidism. Treatment with thyroxine was re-
quired for a diagnosis of hypothyreosis. The diagnoses
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were further validated by information in the patients self-
reported questionnaires. A disease mentioned only in the
self-reported questionnaire that could not be validated in
the records was not registered. To distinguish extra-
articular RA, including RA-associated lung disease from
co-morbidities, the Malmo criteria for RA-associated lung
disease were used [42]. Cumulated pharmacological treat-
ment was registered (months before inclusion and during
the follow up period) on use of corticosteroids and
disease-modifying anti-rheumatic drugs ((DMARDs), i.e.,
methotrexate, sulfasalazine, chloroquine, azathioprine,
mycophenolatmophetil, myocrisine, auranofin, cyclospor-
ine, leflunomid, alkylating cytotoxic agents) including
biological agents (etanercept, adalimumab, infliximab,
anakinra, rituximab). Treatment with non-steroidal anti-
inflammatory drugs (NSAIDs) before inclusion and any
period during the follow up period, was recorded simply
as “yes” or “no”. The regional Ethics Committee at the
University Hospital of Umeå approved this study and all
participants gave their written informed consent in ac-
cordance with the Declaration of Helsinki.
Statistical analysis
Descriptive data collected at baseline and after 5 years are
presented as mean (SD) or as a percentage. For those pa-
tients having a single data point, i.e., ESR, CRP, TJC/SJC,
VAS scales and HAQ, missing from the RA-register data,
the previous value was used to impute data once for each
inflammatory variable assessed, up to 24 months. The pro-
portions of imputations for each variable and registration
were 3.6 % from 0 to 6 months, however that figure in-
creased somewhat up to 24 months and is estimated to be
at most 16 %. Disease activity, DAS28, was calculated ac-
cording to the trapezoid model to evaluate the total bur-
den of disease activity over time, referred to as the area
under the curve (AUC) of DAS28, at 6, 12, and 24 months
after inclusion into the study. Simple and multiple logistic
regression analysis was used to evaluate the association
between prognostic risk factors and the outcomes. Vari-
ables for multiple modeling were chosen based on clinical
assumptions and with respect to the results of simple re-
gression analyses (p <0.05). In multiple models the influ-
ence of age, sex, disease activity (baseline ESR), disease
severity (development of Ex-RA), having a smoking his-
tory at baseline, and ever using corticosteroids, was exam-
ined on different outcome variables; co-morbidity overall,
and composite outcome variables such as pulmonary co-
morbidity (RA-associated and obstructive lung disease)
and endocrine co-morbidity (thyroid disease, osteoporosis,
diabetes, hyperparathyroidism). ESR at baseline was
chosen as a measure of disease activity because data on
baseline ESR was available for more than 95 % of patients
compared with AUC for DAS28 at 24 months, for
which we had fewer data. All p values are two-sided,
and p values ≤0.05 were considered statistically significant.
All calculations were performed using the IBM SPSS
Statistics 21.0 program (SPSS, Chicago, IL, USA).
Results
Demographic data at baseline (T0) and after 5 years (T5)
The mean age at disease onset was 55.6 years (range
18–89 years). Of the 950 patients included at baseline
(T0), 649 (68.3 %) were female and 301 (31.7 %) male. The
mean duration (SD) from the first symptom of rheuma-
toid disease to inclusion into the register was 6.7 (3.5)
months (Table 1).
In all, 53.2 % of patients had one or more co-morbidity at
the onset of RA. The most common co-morbidities at inclu-
sion were hypertension (27.3 %), obstructive pulmonary dis-
ease (asthma and/or COPD) (13.9 %), diabetes (8.0 %),
hypothyroidism (6.3 %) and malignancy (5.0 %). After 5 years
41.0 %, had developed a minimum of one new co-morbidity,
of whom 27.8 % had one co-morbidity, 9.1 %, had two,
3.4 % had three, and 0.7 % had four co-morbidities. The
commonest new co-morbidities were hypertension (15.1 %),
malignancy (7.6 %), stroke/TIA (5.1 %), myocardial infarc-
tion (MI) (4.3 %) and osteoporosis (3.7 %).
Among the patients with obstructive pulmonary disease
at inclusion 39 patients (4.1 %) had COPD and 106
(11.2 %) had asthma. Of these, 13 patients had both
COPD and asthma. After 5 years, 13 patients (1.8 %) had
developed COPD and 4 (0.6 %) asthma.
During follow up, 40 patients (4.9 %) suffered an
extra-articular manifestation. Twelve patients already
had Ex-RA at T0. All of these manifestations constituted
RA-associated lung disease. At T5, 28 patients developed
a new Ex-RA, including 20 patients with RA-associated
lung disease. Thus, of the 40 patients with Ex-RA, at fol-
low up as many as 32 were identified as having RA-
associated lung disease. For analysis of predictors for
new lung disease, a composite variable was created com-
prising obstructive lung disease COPD/asthma and RA-
associated lung disease (n = 37 in all). The composite
variable for a new endocrine disease during 5 years com-
prised 75 patients (10.5 %), including patients with thy-
roid disease (2.4 %), osteoporosis (3.7 %), DM (3.3 %),
and hyperparathyroidism (0.6 %) (Table 2).
Predictors of a new co-morbidity after five years: simple
logistic regression models
In simple regression analyses, co-variates associated with a
new co-morbidity after 5 years were age at inclusion, pres-
ence of co-morbidity at baseline, ESR at baseline, cortico-
steroid therapy (p <0.001 for all), Ex-RA (p <0.01), AUC
DAS28 (24 months) (p <0.05), ever smoking (p = 0.058)
and male gender (p <0.01). The covariate associated with
reduced risk of a new co-morbidity was treatment with a
biological agent (p <0.05) (Table 3).
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Predictors of a new co-morbidity after five years: multiple
logistic regression models
In multiple regression analyses, ESR at baseline was sig-
nificantly associated with a new co-morbidity after
5 years in a model adjusted for age, sex, smoking habits
and corticosteroid therapy (Table 4). In a similar model
substituting ESR with Ex-RA, Ex-RA (OR 2.245 CI
1.036, 4.868); p <0.05) was associated with a new co-
morbidity. In a model evaluating predictors for new lung
co-morbidity, including RA-associated lung disease, and
smoking habit - but not ESR at baseline - was signifi-
cantly associated with the outcome (Table 5). For vari-
ables associated with a new endocrine co-morbidity as
one group, ESR at baseline approached significance (p =
0.10) in a model adjusted for age, sex, smoking habits
and corticosteroid treatment (Table 6). Adjustments for
presence of co-morbidities at baseline had no impact on
any of the presented models.
Table 2 Co-morbidity at baseline and 5 years in patients with
early rheumatoid arthritis
Baseline (n =950) New co-morbidity during
5 years of disease (n = 726)
% %
Co-morbidity overalla 53.2 41.0
Hypertension 27.3 15.1
Asthma/COPD 13.9 (11.2/4.1) 2.4 (0.6/1.8)
Any endocrine disease 19.2 10.5
Diabetes mellitus 8.0 3.3
Hypothyroidism 6.3 1.9




Myocardial infarction 4.5 4.3
Stroke/TIA 3.9 5.1
Values are percent for all. aCo-morbidity defined according to Charlson [40].
bDefined as hypothyroidism, hyperthyroid disease and goiter. COPD chronic
obstructive lung disease, TIA transient ischemic attack
Table 1 Descriptive data at baseline (T0) for 950 patients and at
5-year follow up (T5) in 726 of the patients diagnosed with early
rheumatoid arthritis
Characteristics Values
Age at onset of symptoms, years 55.6 (14.4)
Female/male, T0 649/301 (68.3/31.7)





Disease activity and severity at T0
ESR, mm/h 30.1 (23.2)
CRP, mg/L 20.7 (24.3)
HAQ 0.86 (0.6)
Tender joint count 6.4 (5.7)
Swollen joint count 7.0 (5.2)
VAS pain, mm 43.4 (25.7)
VAS global, mm 44.4 (25.7)
AUC DAS28, 6 months 25.1 (7.2)
AUC DAS28, 12 months 46.2 (13.4)
AUC DAS28, 24 months 86.5 (25.6)
Ex-RA ≤ T5 4.9
Nodules ≤ T5 16.4
Smoking ever, T0 65.8
Treatments
DMARDs within 3 months after T0 90.1
DMARDs ever ≤ T5 97.8
Methotrexate ever ≤ T5 86.9
Biological treatment ever ≤ T5 16.5
Time without DMARDs from symptom
onset, months
6.8 (4.9)
Time without DMARDs T0–T5, months 8.4 (15.7)
NSAIDs ever ≤ T5 84.0
Cox-2 inhibitors ever ≤ T5 26.5
Corticosteroids T0–T5, months 22.2 (23.8)
Corticosteroids ever ≤ T5 71.0
Mean(SD), number or percent. RF rheumatoid factor, ANA anti-nuclear antibody,
ACPA anti-citrullinated protein/peptide antibody (analyzed as anti-CCP2), HLE-SE
human leucocyte antigen-shared epitope, ESR erythrocyte sedimentation rate,
CRP C-reactive protein, HAQ health assessment questionnaire, AUC area under
curve, DAS28 disease activity score in 28 joints, Ex-RA extra articular manifestations
of RA, DMARDs disease modifying anti-rheumatic drugs, NSAIDs non-steroid
anti-inflammatory drugs, Cox-2 cyclo oxygenase 2inhibitors
Table 3 Covariates associated with increased or reduced risk of
a new co-morbidity overall during the first five years in simple
logistic regression analysis
Covariates Odds ratio CI 95 % P value
ESR (T0), mm/h 1.015 1.008, 1.022 <0.001
AUC DAS28 (24 months) 1.008 1.000, 1.016 <0.05
Ex-RA, yes/no 3.247 1.604, 6.574 <0.01
Corticosteroids ever ≤ T5 2.087 1.468, 2.969 <0.001
Biological treatment ever ≤ T5 0.599 0.389, 0.922 <0.05
Smoking, ever (T0) 1.373 0.990, 1.905 0.058
Age at disease onset, years 1.068 1.054, 1.083 <0.001
Sex male/female 1.539 1.118, 2.119 <0.01
Body mass index (T0) 1.034 0.990, 1.080 0.129
Co-morbidity at T0, number 1.459 1.248, 1.704 <0.001
ESR erythrocyte sedimentation rate, T0 baseline, AUC area under the curve,
DAS28 disease activity score in 28 joints, Ex-RA extra-articular disease, T5
five years
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Discussion
The objectives of the present study were to investigate,
first, the presence of co-morbidities in patients with early
RA and the spectrum of new co-morbidities developing
during the first five years following diagnosis, and second,
the impact of inflammation on the development of a new
co-morbidity during the first 5 years following diagnosis.
The presence of co-existing disease was common within
this cohort of patients with early RA. In all, 53.2 % of the
patients had at least one medical condition in addition to
RA, of whom 23 % had more than one co-existing disease
at RA onset. These figures are close to those reported for
cohorts of patients with early RA from North America
(58 % [8]), the Netherlands (66 %, [43]), Great Britain
(31.6 % [10]) and Southern Sweden (43 % [44]). In con-
trast, a recent study reported a lower rate of co-morbidity
with a baseline prevalence of 20 % for all co-morbidities in
patients with early RA [11]. In the present study the
burden of co-existing disease increased during the 5-year
follow up period and 41.0 % developed at least one new
co-morbidity over the first 5 years of disease. Further-
more, these figures are consistent with other reports of an
increasing burden of illness over time [8, 10, 11, 44]. How-
ever, it is difficult to compare the overall disease burden
among the various studies since there is no common def-
inition of co-morbidity. We used the Charlson co-
morbidity index to define the co-morbidity groups. This
index was developed to predict one-year mortality in a
large cohort of patients and comprises a weighting of
diagnosis for mortality risk. The focus of the present study
was, however, the role of inflammation in the context of
the development of co-morbidity. Thus, we only used this
instrument for the purpose of defining co-morbidities.
In this cohort of 950 patients with early RA, the mean
age at onset was 55.6 years and 27.3 % were receiving
treatment for hypertension at inclusion, whilst an add-
itional 15.1 % developed hypertension during the first
5 years of disease. This figure is higher than expected.
The prevalence of hypertension requiring treatment in
Swedes aged 60 years was calculated to be 10 % in 2003
[45]. The occurrence of chronic pulmonary disease, in
this context of COPD and/or asthma, at the onset of RA
was close to 14 %, of whom most had been diagnosed
with asthma. Furthermore, approximately 85 % of the
patients with chronic pulmonary disease (COPD and/or
asthma) were diagnosed before the onset of RA, which
is consistent with previous reports [9, 43]. Previous stud-
ies have shown RA patients to have a higher than ex-
pected risk of COPD [46] and an increased risk of
asthma [47] compared with the general population but
the reported data are conflicting, especially for asthma
[48]. Regarding Ex-RA, almost 5 % of the patient cohort
developed such a complication during the 5-year follow
up period with RA-associated lung disease being the
most common comprising 4 % of the total 5 %. More
than a third already had an RA-associated lung disease
at the onset of RA; a finding that is in keeping with
Koduri et al. [20]. When considering the emerging data
suggesting the mucosal surfaces, i.e., the lung, to be the
potential site for an initial immune dysregulation and
autoantibody generation in the early development of RA
[49], the relatively high proportion of patients with lung
disease involvement at baseline is of great interest. When
we used a multiple model to evaluate predictors of devel-
oping a new lung disease, disease activity, measured as
ESR, had no impact, whereas having ever being a smoker
was independently associated with the outcome.
In univariate analysis cumulative inflammation over
time (i.e., AUC DAS28 after 24 months) was associated
with a new co-morbidity. Furthermore, ESR at inclusion
was independently associated with a new co-morbidity
during the first 5 years in a multiple model adjusted for
Table 4 Covariates associated with a new co-morbidity overall
during the first five years
Co-variates Odds ratio CI 95 % P value
ESR. T0, mm/h 1.008 1.001, 1.016 0.036
Corticosteroids ever ≤ T5 1.760 1.168, 2.654 <0.01
Smoking ever, T0 1.302 0.877, 1.933 0.190
Age at disease onset, years 1.072 1.055, 1.090 <0.001
Sex female/male 1.058 0.720, 1.554 0.775
Multiple logistic regression analysis (n = 623). ESR erythrocyte sedimentation
rate, T0 baseline, T5 five years after baseline
Table 5 Covariates associated with a new lung co-morbidity
(obstructive lung disease, rheumatoid arthritis-associated lung
disease) during the first five years
Covariates Odds ratio CI 95 % P value
ESR, T0, mm/h 1.002 0.988, 1.017 0.760
Smoking ever, T0 6.479 1.925, 21.800 <0.01
Age at disease onset, years 1.043 1.010, 1.078 <0.05
Sex female/male 1.663 0.765, 3.618 0.199
Multiple logistic regression analysis (n = 637). ESR erythrocyte sedimentation
rate, T0 baseline, T5 five years after baseline
Table 6 Covariates associated with new endocrine disease
(thyroid diseases, osteoporosis, diabetes, hyperparathyroidism)
during the first five years
Co-variates Odds ratio CI 95 % P value
ESR (T0), mmHg 1.009 0.998, 1.020 0.101
Corticosteroids ever ≤ T5 1.542 0.792, 3.002 0.202
Smoking ever (T0) 0.761 0.435, 1.332 0.339
Age at disease onset, years 1.052 1.028, 1.077 <0.001
Sex f/m 4.552 2.076, 9.980 <0.001
Multiple logistic regression analysis (n = 625). ESR erythrocyte sedimentation
rate, T0 baseline, T5 five years after baseline
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age, sex, use of corticosteroids and smoking. Also, a
more serious disease, measured by the development of
Ex-RA during the follow up period, was associated with
a new co-morbidity over time. However, others were un-
able to demonstrate that co-morbidity is related to dis-
ease activity [10, 44].
In all, 6.3 % of the patients had hypothyroidism at the
time of RA onset, a finding that is consistent with that
of Raterman et al., who reported an increased risk of
hypothyroidism in female RA patients compared with
controls [50], but in contrast with a recent study report-
ing no increase of hypothyroid diseases in patients with
RA compared to those without [51]. However, both of
these studies reported that hypothyroid disease in RA
patients was associated with increased risk of CVD and
Raterman suggested that RA patients should be screened
for hypothyroidism [50]. In an epidemiological study,
thyroxine substitution was suggested to be associated
with an increased risk of developing RA [52]. In the
present cohort, there were strong gender differences
with an overall four-fold increased risk of endocrine dis-
eases in female patients. The role of inflammation has
been questioned in the context of endocrine disease,
[51] however, we did find indications of increased risk; a
new endocrine co-morbidity, tended to be associated
with higher baseline ESR, and when adjusted for age,
sex, smoking and corticosteroid treatment. During the
5-year follow up period, 7.6 % (n = 54) developed a new
malignancy, the three most frequent forms being pros-
tate cancer (n = 13), gastrointestinal cancer (n = 10) and
lung cancer (n = 10). All of the patients who developed
lung cancer had a history of smoking except one patient
for whom data on smoking status was lacking. Smoking
is a well-known risk factor for both RA and lung cancer,
however, systemic inflammation has also been reported
to be associated with lung cancer [26]. Three patients
had developed lymphoma at follow up. Higher inflam-
matory activity has been shown to be a major risk factor
for lymphoma in RA patients and the chronic inflamma-
tory state associated with RA may be the explanation,
however, treatment with DMARDs did not appear to be
a risk factor in that study [27].
Concerning cardiovascular co-morbidity, 4.3 % of pa-
tients had a new MI and 5.1 % a stroke/TIA during the
follow up period. We analyzed co-morbidity thoroughly in
a previous prospective study [41] and found inflammatory
activity to be harmful in terms of new cardiovascular
events; a conclusion that is in keeping with several other
cross-sectional and retrospective studies [31–33], but at
variance with a smaller study from southern Sweden [44].
We also found that inflammation potentiated the effect of
traditional cardiovascular risk factors [41].
The main strengths of the present study are the pa-
tient group comprising a large regional cohort, and the
prospective design. The study involves few physicians at
each rheumatology center in northern Sweden. Essen-
tially, all patients with newly diagnosed RA in Sweden
are referred to a specialist. Thus, the results for the
present cohort can be regarded as applicable to all pa-
tients with early RA. Furthermore, repeated measure-
ment of the variables associated with inflammation
made it possible to take the variability in disease activity
into account. Conversely, a limitation is the observa-
tional nature of this study with a risk of confounding by
indication when evaluating the efficacy of pharmaco-
logical treatment such as corticosteroids and biologic
agents. In the evaluation of the total burden of disease
activity over time, we have accurate data only up to
24 months. Another limitation is the relatively small
number in each group after any stratification of the data,
which made it difficult to perform sub-group analyses.
As we have classified our patients according to Charlson
[40], we have no reliable data on, for example, mental ill-
nesses such as depression. The most common disease
group of myocardial and vascular diseases, including
hypertension, was the focus of a previous study and has
been presented in detail [41].
Conclusion
In conclusion, co-morbidity was found to be common in
patients with recent onset of RA, and considerable new
co-morbidity developed during the first 5 years of dis-
ease. We were also able to show inflammatory activity,
both at disease onset and accumulated over time, to be
associated with a new co-morbidity during the follow up
period. Furthermore, there was a tendency for inflamma-
tion to predict endocrine disease. Of interest was that
inflammation did not predict a new lung co-morbidity,
but smoking was a strong predictor.
To summarize, in addition to the index disease, patients
with RA appear to have several other medical conditions
at disease onset that add to their disease burden. Thus, in
everyday clinical practice, the patient's disease activity
should be treated not only to prevent any destruction of
joints but also with regard to their specific co-morbid dis-
ease(s). The need to take preventive action through life-
style changes, in particular in relation to smoking, should
be emphasized in the modern care of rheumatics.
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